Elanco Animal Health Inc reported solid revenue growth and improved operational cash flow in 2025, supported by its dual focus on pet and farm animal health products. However, the company incurred a net loss driven by restructuring costs and previously divested business gains influencing comparatives. Looking ahead, Elanco aims for growth through portfolio innovation and geographic expansion amid ongoing pressures from generic competition, antibiotic use regulation, and evolving distribution channels. While operating cash flow supports elevated capital expenditures in manufacturing capacity expansion, substantial indebtedness remains a constraining factor for capital allocation and strategic flexibility.